Atlas Trials

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Clinical trial NCT06795048 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06795048
Sponsor
Hoffmann-La Roche
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration (nAMD)
Start date
2025-03-14
Primary completion
2026-10-20
Enrollment
274

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.